Generic Medicine Info
Should be taken with food. Take immediately after meals.
HLA-B*58:01-positive patient.
Special Precautions
Patient with abnormal Fe storage (including haemochromatosis), thyroid disorder. Not intended for the treatment of an acute gout attack. Renal and hepatic impairment. Children. Pregnancy and lactation. Patients taking allopurinol (300-600 mg) concomitantly with mercaptopurine or azathioprine. Patient Counselling This drug may cause drowsiness or dizziness, if affected, do not drive or operate machinery. Ensure sufficient fluid intake while taking this medicine. Monitoring Parameters Monitor uric acid levels, CBC, LFT and renal function tests. Observe for signs/symptoms of hypersensitivity or hepatotoxicity. Monitor hydration status, therapeutic response, frequency and severity of gouty attacks.
Adverse Reactions
Significant: Bone marrow suppression (e.g. leucopenia, eosinophilia, thrombocytopenia), reversible hepatotoxicity, asymptomatic increase in serum alkaline phosphatase or transaminase levels, renal failure, acute attacks of gout, dissolution of large uric acid renal pelvic stones. Gastrointestinal disorders: Nausea, vomiting, diarrhoea, abdominal pain, dyspepsia, loss of taste, gastritis. General disorders and administration site conditions: Fever. Hepatobiliary disorders: Granulomatous hepatitis, hepatic necrosis, hepatomegaly, cholestatic jaundice, hyperbilirubinaemia. Investigations: Increased blood TSH. Musculoskeletal and connective tissue disorders: Arthralgia, myopathy. Nervous system disorders: Headache, paraesthesia, neuritis, peripheral neuropathy. Psychiatric disorders: Somnolence. Renal and urinary disorders: Uraemia. Respiratory, thoracic and mediastinal disorders: Epistaxis. Skin and subcutaneous tissue disorders: Ecchymosis, alopecia, pruritus, onycholysis, lichen planus, urticaria. Vascular disorders: Vasculitis, necrotising angiitis.
Potentially Fatal: Drug rash and eosinophilia (DRESS), Stevens-Johnson syndrome, toxic epidermal necrolysis, irreversible hepatotoxicity.
Drug Interactions
Reduces the metabolism of azathioprine and mercaptopurine, thus increasing the risk of severe bone marrow toxicity. May prolong the half-life of dicoumarol, chlorpropamide and vidarabine. May increase ciclosporin levels. May increase the risk of hypersensitivity in patients with decreased renal function and receiving thiazide diuretics. May inhibit the metabolism of theophylline. Uricosuric agents (e.g. probenecid) and large doses of salicylate may accelerate the excretion of oxipurinol and may result in reduced efficacy of allopurinol. Increased frequency of skin rash with concomitant ampicillin or amoxicillin.
CIMS Class
Hyperuricemia & Gout Preparations
ATC Classification
M04AA01 - allopurinol ; Belongs to the class of preparations inhibiting uric acid production. Used in the treatment of gout.
Disclaimer: This information is independently developed by CIMS based on allopurinol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in